An Open-Label, Non-Randomized, Phase I Study to Assess the Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib in Patients With Advanced Solid Tumors

Trial Profile

An Open-Label, Non-Randomized, Phase I Study to Assess the Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Rucaparib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Acronyms AME
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 20 Jul 2017 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.
    • 20 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
    • 12 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top